All of the children treated with Evrysdi who had three or more SMN2 copies (n=18), achieved standing and walking (100%) milestones as assessed by Bayley Scales of Infant and Toddler Development, third edition (BSID-III) and Hammersmith Infant Neurological Examination, Module 2 (HINE-2), with most achieving these milestones within World Health Organisation (WHO) windows of typical child development.在有两个SMN2副本(n = 5)的儿童中,全部可以坐下(100%),大多数人可以在两年治疗后独立站立和步行(60%)。经过两年的治疗后,所有儿童都能够口服吞咽和喂食,没有任何儿童需要永久通风。自然史研究表明,如果没有疾病修改治疗,那么患有1型SMA的儿童将无法达到这样的里程碑,也无法生活在两岁的年龄中。